Enjoy complimentary customisation on priority with our Enterprise License!
The hepatic encephalopathy (HE) therapeutics market share is expected to increase by USD 1 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 6.08%.
This hepatic encephalopathy (HE) therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers hepatic encephalopathy (HE) therapeutics market segmentation by product (NADs, antibiotics, and others) and geography (North America, Europe, Asia, and ROW). The hepatic encephalopathy (HE) therapeutics market report also offers information on several market vendors, including Alfasigma Spa, ASKA Pharmaceutical Co. Ltd., Bausch Health Companies Inc., COSMO PHARMACEUTICALS NV, Cumberland Pharmaceuticals Inc., Horizon Therapeutics Plc, Lupin Ltd., Mallinckrodt Plc, Norgine BV, and Rebiotix Inc. among others.
Download the Free Report Sample to Unlock the Hepatic Encephalopathy (HE) Therapeutics Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The availability of patient-focused programs to assist disease management is notably driving the hepatic encephalopathy (HE) therapeutics market growth, although factors such as late and inaccurate diagnosis may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the hepatic encephalopathy (HE) therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Hepatic Encephalopathy (HE) Therapeutics Market Driver
One of the key factors driving growth in the hepatic encephalopathy (HE) therapeutics market in the availability of patient-focused programs to assist disease management. Vendors in the market conduct several programs to help patients manage HE. For instance, Salix conducts the Hepatic Encephalopathy Living Program (H.E.L.P.), which provides support to patients and their caregivers to manage HE. H.E.L.P. provides a 24/7 helpline service that is managed by trained nurses to address queries and make reminder calls about medicine refills and doctor visits. Such programs improve convenience for patients, which increases adherence to therapeutics. The availability of such patient-focused programs to assist with the management of HE will drive the growth of the global HE therapeutics market during the forecast period.
Key Hepatic Encephalopathy (HE) Therapeutics Market Trend
The technological advances is another factor supporting the hepatic encephalopathy (HE) therapeutics market share growth. The adoption of advanced technology to improve the safety profile of the therapeutics used to treat HE is increasing. For instance, the Multi Matrix (MMX) technology, which is offered by COSMO PHARMACEUTICALS, is one such promising development. The MMX technology helps deliver antibiotics directly into the colon. The direct delivery of the drug to the colon helps in preventing the unwanted effects on the beneficial bacterial flora in the GI tract. The controlled release of APIs by the tablet over the colon's length simplifies the application for patients and enables the topical application of APIs to complete a part of the bowel surface, which is inflamed. The MMX technology has the potential to be used for other colon-related diseases. Hence, such technological advances will drive the growth of the global HE therapeutics market during the forecast period.
Key Hepatic Encephalopathy (HE) Therapeutics Market Challenge
The late and inaccurate diagnosis will be a major challenge for the hepatic encephalopathy (HE) therapeutics market during the forecast period. The symptoms of HE are non-specific. They include personality changes, slurred speech, poor coordination, lethargy, confusion, trembling hands, and bad breath. The symptoms are usually subtle and may be attributed incorrectly to other causes. This can cause delays in diagnosis or inaccurate diagnosis. The absence of an agreed standard procedure or diagnostic test is also a challenge that compounds concerns about the diagnosis of the disease. Hence, the late and inaccurate diagnosis of HE could affect the growth of the global HE therapeutics market during the forecast period.
This hepatic encephalopathy (HE) therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the global hepatic encephalopathy (HE) therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the hepatic encephalopathy (HE) therapeutics market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the hepatic encephalopathy (HE) therapeutics market encompasses successful business strategies deployed by the key vendors. The hepatic encephalopathy (HE) therapeutics market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
Alfasigma Spa - The company offers rifaximin-a, a poorly absorbed and therefore safe antibiotic, used in the treatment of gastrointestinal tract disorders.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The hepatic encephalopathy (HE) therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the hepatic encephalopathy (HE) therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
For more insights on the market share of various regions Request for a FREE sample now!
41% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for hepatic encephalopathy (HE) therapeutics in North America. Market growth in this region will be faster than the growth of the market in the European and ROW regions.
The presence of the US, which is the largest market for pharmaceuticals in the world will facilitate the hepatic encephalopathy (HE) therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The hepatic encephalopathy (HE) therapeutics market share growth by the NADs segment will be significant during the forecast period. The NADs segment will grow moderately during the forecast period. Although rifaximin is better tolerated, NADs are preferred as the first line of therapy due to the side effects associated with antibiotics, such as alterations in gut flora. NADs are also inexpensive. Hence, the demand for NAD HE therapeutics is expected to increase during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the hepatic encephalopathy (HE) therapeutics market size and actionable market insights on post COVID-19 impact on each segment.
Antibiotics market - The Market share is expected to increase by USD 4.44 billion from 2019 to 2024, and the market's growth momentum will accelerate at a CAGR of 3.03%.
Hepatic Encephalopathy (HE) Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.08% |
Market growth 2021-2025 |
$ 1 billion |
Market structure |
Fragmented |
YoY growth (%) |
3.05 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 41% |
Key consumer countries |
US, UK, Germany, China, and Canada |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Alfasigma Spa, ASKA Pharmaceutical Co. Ltd., Bausch Health Companies Inc., COSMO PHARMACEUTICALS NV, Cumberland Pharmaceuticals Inc., Horizon Therapeutics Plc, Lupin Ltd., Mallinckrodt Plc, Norgine BV, and Rebiotix Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.